CordenPharma’s expansion will include the addition of new production lines which will be merged into the lipid manufacturing process in April 2021.
CordenPharma announced on April 19, 2021 that it is expanding its lipid purification capacity at its Colorado site.
According to a CordenPharma press release, the expansion will include the addition of new production lines, which will be merged into the lipid manufacturing process in April 2021. By July 2021, the company expects a decrease in lipid shipment delivery time due to the expansion.
“CordenPharma is proud to contribute this major capital expansion to increase important lipid production for the global market,” said Michael Quirmbach, CEO and president, CordenPharma. “We have drawn upon longstanding expertise in specialized lipids to create an even stronger integrated network of facilities to support current and future projects.”
The company, who has also expanded its lipid supply chain at its facilities in Switzerland and France, manufactures four lipids used to formulate messenger RNA (mRNA)-based vaccines. They include:
Source: CordenPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.